A. Olsen

发表

[8-oxoguanosine as a marker of neoplastic process in brain].

J. Barciszewski, G. Siboska, S. Nowak, 1999, Neurologia i neurochirurgia polska.

XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair

Katsuhiro Hanada, A. D’Andrea, P. McHugh, 2009, Molecular and Cellular Biology.

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

M. Ranson, P. Price, J. Matthews, 2010, Clinical Cancer Research.

Quantitative Analysis of Survivin Protein Expression and Its Therapeutic Depletion by an Antisense Oligonucleotide in Human Lung Tumors

P. McHugh, D. Talbot, David Breen, 2012, Molecular therapy. Nucleic acids.

PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation

G. Stewart, P. McHugh, N. Lakin, 2018, bioRxiv.

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

A. Harris, A. Boddy, N. Curtin, 2008, Clinical Cancer Research.

PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation

G. Stewart, P. McHugh, N. Lakin, 2018, Nature Communications.

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

Adrian L Harris, A. Harris, A. Boddy, 2005, Clinical Cancer Research.

PARP 1 and PARP 2 stabilise replication forks at base excision repair intermediates through Fbh 1-dependent Rad 51 regulation

G. Stewart, P. McHugh, N. Lakin, 2018 .

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

A. Harris, A. Boddy, N. Curtin, 2008, Clinical Cancer Research.